Cargando…
Prophylactic Anti-Cytomegalovirus Hyperimmunoglobulin in Critically Ill Liver Transplant Patients: Impact on Early Immunology and Survival
Background: Anti-cytomegalovirus hyperimmunoglobulin (CMVIg) was shown to provide beneficial immunodulatory properties beyond antiviral efficacies. The aim of this retrospective study was to assess the impact of prophylactic CMVIg treatment on early outcome following liver transplantation (LT) in cr...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141244/ https://www.ncbi.nlm.nih.gov/pubmed/32121313 http://dx.doi.org/10.3390/jcm9030656 |
_version_ | 1783519154753503232 |
---|---|
author | Kornberg, Arno Witt, Ulrike Kornberg, Jennifer Müller, Katharina Friess, Helmut Thrum, Katharina |
author_facet | Kornberg, Arno Witt, Ulrike Kornberg, Jennifer Müller, Katharina Friess, Helmut Thrum, Katharina |
author_sort | Kornberg, Arno |
collection | PubMed |
description | Background: Anti-cytomegalovirus hyperimmunoglobulin (CMVIg) was shown to provide beneficial immunodulatory properties beyond antiviral efficacies. The aim of this retrospective study was to assess the impact of prophylactic CMVIg treatment on early outcome following liver transplantation (LT) in critically ill patients. Methods: Forty-three cirrhotic patients requiring pre-LT intensive care due to multiorgan failure were analyzed. Twenty-eight patients with enhanced CMV risk (D+/R+; D+/R−; D−/R+) received prophylactic CMVIg for a minimum of 7 days, while 15 patients (D−/R−) did not. Results: Post-transplantation rates of intra-abdominal infections (28% vs. 61.1%; p = 0.03), Epstein–Barr virus infections (0% vs. 33.3%; p = 0.034), allograft rejections (0% vs. 22.2%; p = 0.013) and sepsis-related mortality (4% vs. 27.8%; p = 0.026) were significantly lower, whereas incidence of CMV infections (4% vs. 22.2%; p = 0.066) tended to be lower in the CMVIg subset. In multivariate analysis, only pretransplant elevated serum lactate level (hazard ratio = 34.63; p = 0.009) and absence of CMVIg therapy (hazard ratio = 21.76; p = 0.023) were identified as independent promoters of 3-month mortality. Conclusion: Prophylactic treatment with CMVIg reduces predisposition for severe immunological and septic events and, thereby, early mortality in critically ill liver recipients. |
format | Online Article Text |
id | pubmed-7141244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71412442020-04-10 Prophylactic Anti-Cytomegalovirus Hyperimmunoglobulin in Critically Ill Liver Transplant Patients: Impact on Early Immunology and Survival Kornberg, Arno Witt, Ulrike Kornberg, Jennifer Müller, Katharina Friess, Helmut Thrum, Katharina J Clin Med Article Background: Anti-cytomegalovirus hyperimmunoglobulin (CMVIg) was shown to provide beneficial immunodulatory properties beyond antiviral efficacies. The aim of this retrospective study was to assess the impact of prophylactic CMVIg treatment on early outcome following liver transplantation (LT) in critically ill patients. Methods: Forty-three cirrhotic patients requiring pre-LT intensive care due to multiorgan failure were analyzed. Twenty-eight patients with enhanced CMV risk (D+/R+; D+/R−; D−/R+) received prophylactic CMVIg for a minimum of 7 days, while 15 patients (D−/R−) did not. Results: Post-transplantation rates of intra-abdominal infections (28% vs. 61.1%; p = 0.03), Epstein–Barr virus infections (0% vs. 33.3%; p = 0.034), allograft rejections (0% vs. 22.2%; p = 0.013) and sepsis-related mortality (4% vs. 27.8%; p = 0.026) were significantly lower, whereas incidence of CMV infections (4% vs. 22.2%; p = 0.066) tended to be lower in the CMVIg subset. In multivariate analysis, only pretransplant elevated serum lactate level (hazard ratio = 34.63; p = 0.009) and absence of CMVIg therapy (hazard ratio = 21.76; p = 0.023) were identified as independent promoters of 3-month mortality. Conclusion: Prophylactic treatment with CMVIg reduces predisposition for severe immunological and septic events and, thereby, early mortality in critically ill liver recipients. MDPI 2020-02-29 /pmc/articles/PMC7141244/ /pubmed/32121313 http://dx.doi.org/10.3390/jcm9030656 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kornberg, Arno Witt, Ulrike Kornberg, Jennifer Müller, Katharina Friess, Helmut Thrum, Katharina Prophylactic Anti-Cytomegalovirus Hyperimmunoglobulin in Critically Ill Liver Transplant Patients: Impact on Early Immunology and Survival |
title | Prophylactic Anti-Cytomegalovirus Hyperimmunoglobulin in Critically Ill Liver Transplant Patients: Impact on Early Immunology and Survival |
title_full | Prophylactic Anti-Cytomegalovirus Hyperimmunoglobulin in Critically Ill Liver Transplant Patients: Impact on Early Immunology and Survival |
title_fullStr | Prophylactic Anti-Cytomegalovirus Hyperimmunoglobulin in Critically Ill Liver Transplant Patients: Impact on Early Immunology and Survival |
title_full_unstemmed | Prophylactic Anti-Cytomegalovirus Hyperimmunoglobulin in Critically Ill Liver Transplant Patients: Impact on Early Immunology and Survival |
title_short | Prophylactic Anti-Cytomegalovirus Hyperimmunoglobulin in Critically Ill Liver Transplant Patients: Impact on Early Immunology and Survival |
title_sort | prophylactic anti-cytomegalovirus hyperimmunoglobulin in critically ill liver transplant patients: impact on early immunology and survival |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141244/ https://www.ncbi.nlm.nih.gov/pubmed/32121313 http://dx.doi.org/10.3390/jcm9030656 |
work_keys_str_mv | AT kornbergarno prophylacticanticytomegalovirushyperimmunoglobulinincriticallyilllivertransplantpatientsimpactonearlyimmunologyandsurvival AT wittulrike prophylacticanticytomegalovirushyperimmunoglobulinincriticallyilllivertransplantpatientsimpactonearlyimmunologyandsurvival AT kornbergjennifer prophylacticanticytomegalovirushyperimmunoglobulinincriticallyilllivertransplantpatientsimpactonearlyimmunologyandsurvival AT mullerkatharina prophylacticanticytomegalovirushyperimmunoglobulinincriticallyilllivertransplantpatientsimpactonearlyimmunologyandsurvival AT friesshelmut prophylacticanticytomegalovirushyperimmunoglobulinincriticallyilllivertransplantpatientsimpactonearlyimmunologyandsurvival AT thrumkatharina prophylacticanticytomegalovirushyperimmunoglobulinincriticallyilllivertransplantpatientsimpactonearlyimmunologyandsurvival |